NICOLE MELET: Open Payments
NPI 1477657971 · SAN FRANCISCO, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,459 in 175 payments from 19 companies in 2025. Trend: 2023 $4,135 · 2024 $5,749 · 2025 $4,459
Food & beverage: $4,394Education: $65
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 21 | $693 |
| LEO Pharma Inc. | 27 | $628 |
| ABBVIE INC. | 20 | $555 |
| GENZYME CORPORATION | 14 | $440 |
| Regeneron Healthcare Solutions, Inc. | 11 | $281 |
| Arcutis Biotherapeutics, Inc. | 17 | $280 |
| Lilly USA, LLC | 10 | $252 |
| UCB, Inc. | 10 | $249 |
| Galderma Laboratories, L.P. | 11 | $223 |
| Incyte Corporation | 8 | $199 |
Products named: TREMFYA, DUPIXENT, ADBRY, Zoryve, RINVOQ, SKYRIZI, TALTZ, Bimzelx.
Industry payments across CA — which companies pay providers there.
